Previous therapy with any PD-1 or PD-L1 inhibitor including durvalumab or anti-CTLA4 (including tremelimumab) for any malignancy.
Previous treatment with a CTLA-4, PD-1, or PD-L1 inhibitor, including prior treatment with either durvalumab or tremelimumab
Prior systemic anti-cancer therapy of any kind for RCC, including but not limited to any approved agent or any previous treatment with a PD1 or PD-L1 inhibitor including durvalumab; no previous treatment with immunotherapy for any malignancy including cytokine, anti-tumor vaccine, T-cell activator, co-stimulator or immune checkpoint inhibitor
Prior immunotherapy including but not limited to anti-CTLA4, including tremelimumab anti-PD-1, and anti-PD-L1, including durvalumab.
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4 inhibitor including tremelimumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD-1 or PD-L1 inhibitor, including but not limited to: nivolumab, atezolizumab, pembrolizumab, or durvalumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab.
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab, and therapeutic anticancer vaccine
Previous treatment with Anti-CTLA-4 including tremelimumab or PD1/PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab
Any previous treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapy, including durvalumab and tremelimumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab
Any previous treatment with adoptive T cells therapy, a PD1 or PDL1 inhibitor, including durvalumab or any anti-CTLA4 therapy, including tremelimumab.
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab
History of discontinuation of any previous treatment with PARP inhibitors, including olaparib, or a PD-1 or PD-L1 inhibitor, including durvalumab or anti-CTLA4 antibody, including tremelimumab due to toxicity
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4), including tremelimumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including MEDI4736
Previous therapy with any PD1 or PD-L1 inhibitor (including durvalumab) for any malignancy.
Prior treatment with an anti-CTLA-4, including tremelimumab PD-1 or PD-L1 inhibitor, including durvalumab
History of hypersensitivity to durvalumab or tremelimumab or any CTLA4, PD1, or PDL-1 inhibitor
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD-1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD-1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA-4, including tremelimumab
Any previous treatment with an anti-CTLA4, including tremelimumab or any previous treatment with a PD1 or PDL1 inhibitor
Any previous treatment with a PD-1 or PD-L1 inhibitor, including durvalumab or any anti-CTLA4, including tremelimumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
Any previous treatment with a PD-1 or PD-L1 inhibitor, including durvalumab or an anti- CTLA-4, including tremelimumab
